Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated June 2026
A woman in her early 40s reports persistent fatigue, near-zero libido, and difficulty concentrating. Her estrogen levels are normal. Her thyroid is fine. Her gynecologist tells her everything looks fine. What nobody ordered was a free testosterone level with SHBG. When those results come back, her SHBG is elevated at 90 nmol/L and her free testosterone is essentially undetectable.
This scenario comes up consistently in the ExcelMale community - not just for men, but for women whose partners, or women themselves, are trying to understand why standard hormone panels keep showing nothing wrong.
Testosterone is not a male-only hormone. Women produce it in the adrenal glands (roughly 50% of output), in the ovaries (about 25%), and through peripheral conversion of adrenal precursors like DHEA. Production peaks in a woman's mid-20s and drops by about half by age 40 - before significant ovarian estrogen decline begins.
The symptoms mirror what men with low testosterone report: fatigue, low sex drive, muscle weakness, brain fog, and mood changes. They are also indistinguishable from perimenopause, depression, and thyroid problems, which is part of why low testosterone in women is chronically underdiagnosed.
Low testosterone in women develops gradually, which makes it easy to attribute to aging or stress. The symptoms that matter clinically are the ones that represent a change from an earlier baseline.
The most documented symptom is reduced sexual desire - specifically the kind not explained by relationship issues or situational stress. This is what clinicians call hypoactive sexual desire disorder (HSDD), which affects an estimated 10-15% of premenopausal women and a higher proportion post-menopausally. A 2022 review in the International Journal of Impotence Research found a positive correlation between free testosterone levels and sexual desire, with DHEA and androstenedione also tracking with desire scores.
Beyond libido, women with low testosterone frequently describe persistent fatigue that does not improve with rest, mental fog, and emotional flatness. Some notice loss of muscle mass alongside increased abdominal fat. Bone density is another concern: androgens contribute to bone maintenance in women, and low testosterone correlates with reduced bone mineral density independent of estrogen status.
Thinning pubic or axillary hair is one of the less-discussed signs. So is reduced skin sensitivity and vaginal tissue changes - tissues that depend partly on androgens for their health and responsiveness.
The core challenge: none of these symptoms point unambiguously to low testosterone. A good clinician evaluates them in the context of lab results rather than treating numbers in isolation.
Total testosterone in women normally ranges from about 15 to 70 ng/dL - roughly 10 to 15 times lower than in healthy men. Levels vary with the menstrual cycle (slightly higher near ovulation), time of day (morning draws give better consistency), age, and body composition.
Unlike men, where a total testosterone below 300 ng/dL is a widely cited clinical threshold, women have no single universally agreed-upon cutoff for deficiency. The 2021 ISSWSH Clinical Practice Guideline states explicitly that total testosterone levels should not be used to diagnose HSDD but can serve as a useful baseline before and during treatment. The diagnosis relies on symptom assessment and ruling out other causes.
Standard immunoassay testosterone tests are calibrated for men's ranges. They lack the sensitivity to reliably distinguish 15 ng/dL from 30 ng/dL in a woman. Liquid chromatography-tandem mass spectrometry (LC/MS/MS) is the only assay method accurate enough to be clinically useful at female testosterone ranges. Most commercial labs now offer LC/MS/MS, but it must be ordered specifically.
Free testosterone - the fraction not bound to SHBG or albumin - represents 1-3% of total testosterone and is the only fraction that can enter cells and activate androgen receptors. In women, because SHBG levels are typically two to three times higher than in men, the bound-to-free ratio is more extreme. A woman can show total testosterone in the normal range while carrying almost no usable free testosterone.
The best measurement is free testosterone by equilibrium dialysis or equilibrium ultrafiltration - both gold-standard methods available through LabCorp and Quest. Calculated free T from total testosterone and SHBG is an acceptable alternative when direct measurement is unavailable. The 'direct free testosterone' immunoassay should not be used for women; multiple studies have confirmed it is inaccurate at female range levels.
The free androgen index (FAI = total T x 100 / SHBG) is occasionally used as a surrogate in women and correlates reasonably well with measured free T. The Endocrine Society notes the FAI works better as a free T surrogate in women than in men, partly because SHBG dominates free T determination in women given lower androgen production rates.
Table 1. Testosterone testing methods and their reliability for evaluating androgen status in women.
SHBG is produced in the liver, and estrogens are among the most potent drivers of its production. Women normally have higher SHBG than men - and anything that raises estrogen exposure will compress free testosterone even when total testosterone stays constant.
Oral estrogen-containing contraceptives are the most common culprit. Switching from an oral combined pill to a progestin-only IUD or non-hormonal contraception can significantly raise free testosterone within weeks. Oral estrogen HRT creates the same issue; transdermal estrogen avoids the hepatic first-pass effect and produces far smaller SHBG increases.
Other factors that elevate SHBG in women: hyperthyroidism (thyroid hormones directly stimulate SHBG production), liver inflammation, severe caloric restriction or eating disorders, and certain anticonvulsants. When SHBG is elevated, even modest doses of exogenous testosterone get partially bound rather than staying in the free, active fraction.
The 2021 ISSWSH guideline specifically notes that women with elevated SHBG concentrations are less likely to experience benefit from testosterone therapy - meaning SHBG needs to be part of the treatment picture, not just T levels alone.
Most women lose about half their testosterone between their mid-20s and early 40s, before significant ovarian estrogen decline begins. This age-related fall is driven largely by declining adrenal production of DHEA and DHEAS, the precursor hormones that peripheral tissues convert into testosterone.
The most abrupt cause is surgical. Bilateral oophorectomy (removal of both ovaries) causes an immediate drop in total testosterone of roughly 50%. Women who undergo this procedure often report the impact within weeks: sudden fatigue, vanishing libido, and mood changes that respond poorly to estrogen replacement alone.
Other common causes include:
Post-menopausally, when ovarian output falls sharply, peripheral conversion of adrenal DHEA becomes the dominant source of androgens. This is why DHEA-S is a particularly informative test in older women.
There is no FDA-approved testosterone product for women in the United States. Treatment is off-label, using compounded formulations or low-dose male products dosed for female physiology. This is not fringe practice. It is endorsed by the Endocrine Society, ISSWSH, and the 2019 Global Consensus Position Statement signed by representatives of 10 international societies.
The evidence is strongest for HSDD in post-menopausal women. Multiple randomized controlled trials show transdermal testosterone improves sexual desire, frequency of satisfying sexual events, and sexual responsiveness in this group. The ISSWSH recommends a 3-to-6-month trial; if there is no meaningful response by 6 months, treatment should be discontinued.
Transdermal delivery is the standard of care. The liver's first-pass effect matters here: oral testosterone raises SHBG, which partially defeats the purpose. Transdermal bypasses this entirely.
Compounded testosterone creams or gels, typically dosed at 0.5 to 2 mg per day, are the most common approach in US clinical practice. Some practitioners use commercially available male testosterone gels with dose adjustment to female physiologic ranges. The goal is to maintain total testosterone within the premenopausal normal range - roughly 15 to 70 ng/dL. Monitoring every 6 to 12 weeks initially helps catch levels creeping too high. At supraphysiologic doses, side effects include acne, increased facial or body hair, and rarely voice changes. These are the signal to reduce dose, not to stop treatment.
DHEA is a useful option for women who prefer a less aggressive approach or who are not candidates for direct testosterone therapy. Oral DHEA at 25 to 50 mg per day raises testosterone modestly, particularly in post-menopausal women where adrenal DHEA production has declined. A 2021 review confirmed that DHEA is a sex hormone precursor and that its age-related decline correlates with loss of libido and energy. Prasterone (Intrarosa), a vaginally administered DHEA product, holds specific FDA approval for painful sex during menopause - a narrower indication than systemic DHEA, but supported by controlled trial data.
Resistance training raises androgen levels in women, though the effect is smaller than in men. It remains worth incorporating for its independent benefits on bone density and metabolic health.
Switching from oral to non-oral contraception is one of the highest-impact changes a woman can make when SHBG suppression is the primary driver. Oral contraceptives remain the most common iatrogenic cause of SHBG elevation and free testosterone suppression in reproductive-age women.
Sleep quality matters more than many women expect. Androgen secretion is tied to slow-wave sleep, and chronic sleep restriction leads to measurable drops in androgens. Stress reduction addresses the cortisol-DHEA axis: elevated cortisol competes with DHEA production in the adrenal glands, and prolonged high stress reduces the availability of the upstream precursor pregnenolone for sex hormone synthesis.
Not at the same dose. Male formulations are designed for doses 10 to 20 times what a woman needs. A typical male starting dose of 50 mg testosterone gel would push a woman's total testosterone well above the physiologic female range, causing androgenic side effects including facial hair, acne, and clitoral enlargement. The formulations themselves are appropriate; the dose has to be scaled down substantially, which usually requires compounding or very careful fractionation of male products.
The minimum useful panel: total testosterone by LC/MS/MS, free testosterone by equilibrium dialysis or equilibrium ultrafiltration, and SHBG. Adding DHEA-S gives information about adrenal androgen reserve. Estradiol and thyroid function (TSH, Free T3, Free T4) help rule out confounders. The DiscountedLabs Women's Hormone Panel includes DHEA-S, estradiol, progesterone, total testosterone by LC/MS/MS, free testosterone by equilibrium ultrafiltration, TSH, Free T3, and Free T4 - a comprehensive starting point without a doctor's order.
Yes. This is the most commonly missed scenario in women's hormone testing. A woman with total testosterone of 45 ng/dL and SHBG of 100 nmol/L can have a free testosterone level below the detection limit of most assays. Symptoms of androgen deficiency - fatigue, low libido, muscle loss - will be present despite a reassuring total T number. Treating to a total T target without addressing SHBG or switching to transdermal estrogen will not resolve the problem.
The evidence is clearest for HSDD specifically, not for general mood or energy in women without sexual desire complaints. Some women report improved energy and emotional resilience, but this likely reflects secondary benefit - better sleep, improved libido, restored sense of well-being - rather than a direct antidepressant mechanism. A 2025 review in BJPsych Bulletin noted that while testosterone influences mood-related pathways, randomized controlled trial data for depression are not robust enough to support routine prescribing for mood alone.
Most women notice changes in sexual desire and energy within 4 to 8 weeks of reaching target levels. Full benefit typically takes 3 to 6 months. The ISSWSH guideline recommends evaluating response at the 6-month mark before deciding whether to continue.
One thing most lab reports won't show you: total testosterone alone is rarely sufficient to evaluate androgen status in women. Free testosterone and SHBG together tell a far more complete story. If SHBG is driving free T toward zero, the treatment approach changes entirely - sometimes without needing any exogenous testosterone at all, just a switch from oral to transdermal estrogen.
For women pursuing this conversation with a provider, the practical starting point is a baseline panel: total T by LC/MS/MS, free T by equilibrium dialysis or ultrafiltration, SHBG, and DHEA-S together. The ISSWSH guideline recommends symptom evaluation first and lab confirmation second. Numbers don't diagnose HSDD; symptoms do.
Men on TRT often bring their partners into these conversations, having seen firsthand how hormone optimization changed their own quality of life. That shared curiosity is what drives the ExcelMale community forward. For further reading, see the ExcelMale SHBG Complete Guide and the ExcelMale HRT in Women forum.
ExcelMale.com is one of the largest and most active online communities for men and women exploring hormone optimization, with over 24,000 members and more than 20 years of peer-to-peer discussion on TRT, peptides, sexual health, and metabolic medicine. The forum was founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, a long-term TRT patient and patient advocate with more than 34 years of personal experience with hormone therapy.
A woman in her early 40s reports persistent fatigue, near-zero libido, and difficulty concentrating. Her estrogen levels are normal. Her thyroid is fine. Her gynecologist tells her everything looks fine. What nobody ordered was a free testosterone level with SHBG. When those results come back, her SHBG is elevated at 90 nmol/L and her free testosterone is essentially undetectable.
This scenario comes up consistently in the ExcelMale community - not just for men, but for women whose partners, or women themselves, are trying to understand why standard hormone panels keep showing nothing wrong.
Testosterone is not a male-only hormone. Women produce it in the adrenal glands (roughly 50% of output), in the ovaries (about 25%), and through peripheral conversion of adrenal precursors like DHEA. Production peaks in a woman's mid-20s and drops by about half by age 40 - before significant ovarian estrogen decline begins.
The symptoms mirror what men with low testosterone report: fatigue, low sex drive, muscle weakness, brain fog, and mood changes. They are also indistinguishable from perimenopause, depression, and thyroid problems, which is part of why low testosterone in women is chronically underdiagnosed.
What Are the Signs and Symptoms of Low Testosterone in Women?
Low testosterone in women develops gradually, which makes it easy to attribute to aging or stress. The symptoms that matter clinically are the ones that represent a change from an earlier baseline.
The most documented symptom is reduced sexual desire - specifically the kind not explained by relationship issues or situational stress. This is what clinicians call hypoactive sexual desire disorder (HSDD), which affects an estimated 10-15% of premenopausal women and a higher proportion post-menopausally. A 2022 review in the International Journal of Impotence Research found a positive correlation between free testosterone levels and sexual desire, with DHEA and androstenedione also tracking with desire scores.
Beyond libido, women with low testosterone frequently describe persistent fatigue that does not improve with rest, mental fog, and emotional flatness. Some notice loss of muscle mass alongside increased abdominal fat. Bone density is another concern: androgens contribute to bone maintenance in women, and low testosterone correlates with reduced bone mineral density independent of estrogen status.
Thinning pubic or axillary hair is one of the less-discussed signs. So is reduced skin sensitivity and vaginal tissue changes - tissues that depend partly on androgens for their health and responsiveness.
The core challenge: none of these symptoms point unambiguously to low testosterone. A good clinician evaluates them in the context of lab results rather than treating numbers in isolation.
What Is a Normal Testosterone Level for Women?
Total testosterone in women normally ranges from about 15 to 70 ng/dL - roughly 10 to 15 times lower than in healthy men. Levels vary with the menstrual cycle (slightly higher near ovulation), time of day (morning draws give better consistency), age, and body composition.
Unlike men, where a total testosterone below 300 ng/dL is a widely cited clinical threshold, women have no single universally agreed-upon cutoff for deficiency. The 2021 ISSWSH Clinical Practice Guideline states explicitly that total testosterone levels should not be used to diagnose HSDD but can serve as a useful baseline before and during treatment. The diagnosis relies on symptom assessment and ruling out other causes.
Standard immunoassay testosterone tests are calibrated for men's ranges. They lack the sensitivity to reliably distinguish 15 ng/dL from 30 ng/dL in a woman. Liquid chromatography-tandem mass spectrometry (LC/MS/MS) is the only assay method accurate enough to be clinically useful at female testosterone ranges. Most commercial labs now offer LC/MS/MS, but it must be ordered specifically.
Free vs. Total Testosterone in Women: Which Number Actually Matters?
Free testosterone - the fraction not bound to SHBG or albumin - represents 1-3% of total testosterone and is the only fraction that can enter cells and activate androgen receptors. In women, because SHBG levels are typically two to three times higher than in men, the bound-to-free ratio is more extreme. A woman can show total testosterone in the normal range while carrying almost no usable free testosterone.
The best measurement is free testosterone by equilibrium dialysis or equilibrium ultrafiltration - both gold-standard methods available through LabCorp and Quest. Calculated free T from total testosterone and SHBG is an acceptable alternative when direct measurement is unavailable. The 'direct free testosterone' immunoassay should not be used for women; multiple studies have confirmed it is inaccurate at female range levels.
The free androgen index (FAI = total T x 100 / SHBG) is occasionally used as a surrogate in women and correlates reasonably well with measured free T. The Endocrine Society notes the FAI works better as a free T surrogate in women than in men, partly because SHBG dominates free T determination in women given lower androgen production rates.
| Test Method | Accuracy at Female Ranges | Recommendation |
|---|---|---|
| Standard immunoassay (total T) | Poor; overcounts at low values | Not recommended for women |
| LC/MS/MS (total T) | High; sensitive to 1-3 ng/dL | Preferred method for total T |
| Direct free T immunoassay | Poor at female range levels | Not recommended for women |
| Free T by equilibrium dialysis | Gold standard | Preferred for free testosterone |
| Free T by equilibrium ultrafiltration | Near gold standard | Accurate and widely available |
| Free Androgen Index (FAI) | Correlates well in women | Acceptable when direct free T unavailable |
How Does High SHBG Affect Free Androgen Levels in Women?
SHBG is produced in the liver, and estrogens are among the most potent drivers of its production. Women normally have higher SHBG than men - and anything that raises estrogen exposure will compress free testosterone even when total testosterone stays constant.
Oral estrogen-containing contraceptives are the most common culprit. Switching from an oral combined pill to a progestin-only IUD or non-hormonal contraception can significantly raise free testosterone within weeks. Oral estrogen HRT creates the same issue; transdermal estrogen avoids the hepatic first-pass effect and produces far smaller SHBG increases.
Other factors that elevate SHBG in women: hyperthyroidism (thyroid hormones directly stimulate SHBG production), liver inflammation, severe caloric restriction or eating disorders, and certain anticonvulsants. When SHBG is elevated, even modest doses of exogenous testosterone get partially bound rather than staying in the free, active fraction.
The 2021 ISSWSH guideline specifically notes that women with elevated SHBG concentrations are less likely to experience benefit from testosterone therapy - meaning SHBG needs to be part of the treatment picture, not just T levels alone.
What Causes Low Testosterone in Women?
Most women lose about half their testosterone between their mid-20s and early 40s, before significant ovarian estrogen decline begins. This age-related fall is driven largely by declining adrenal production of DHEA and DHEAS, the precursor hormones that peripheral tissues convert into testosterone.
The most abrupt cause is surgical. Bilateral oophorectomy (removal of both ovaries) causes an immediate drop in total testosterone of roughly 50%. Women who undergo this procedure often report the impact within weeks: sudden fatigue, vanishing libido, and mood changes that respond poorly to estrogen replacement alone.
Other common causes include:
- Oral contraceptives: by raising SHBG, they reduce free T even when total T stays in range
- Adrenal insufficiency: the adrenal glands supply precursors for approximately 50% of female testosterone; Addison's disease or pituitary insufficiency can substantially cut this
- Hypothalamic suppression: high chronic stress, excessive exercise volume, or very low body weight can suppress LH and reduce ovarian androgen output
- Glucocorticoid medications: reduce adrenal DHEA production directly
- Natural aging: adrenal DHEA output may be 50-70% below peak levels by the time of menopause
Post-menopausally, when ovarian output falls sharply, peripheral conversion of adrenal DHEA becomes the dominant source of androgens. This is why DHEA-S is a particularly informative test in older women.
How Is Low Testosterone in Women Treated?
There is no FDA-approved testosterone product for women in the United States. Treatment is off-label, using compounded formulations or low-dose male products dosed for female physiology. This is not fringe practice. It is endorsed by the Endocrine Society, ISSWSH, and the 2019 Global Consensus Position Statement signed by representatives of 10 international societies.
The evidence is strongest for HSDD in post-menopausal women. Multiple randomized controlled trials show transdermal testosterone improves sexual desire, frequency of satisfying sexual events, and sexual responsiveness in this group. The ISSWSH recommends a 3-to-6-month trial; if there is no meaningful response by 6 months, treatment should be discontinued.
Testosterone Creams and DHEA: What Are the Real Options?
Transdermal delivery is the standard of care. The liver's first-pass effect matters here: oral testosterone raises SHBG, which partially defeats the purpose. Transdermal bypasses this entirely.
Compounded testosterone creams or gels, typically dosed at 0.5 to 2 mg per day, are the most common approach in US clinical practice. Some practitioners use commercially available male testosterone gels with dose adjustment to female physiologic ranges. The goal is to maintain total testosterone within the premenopausal normal range - roughly 15 to 70 ng/dL. Monitoring every 6 to 12 weeks initially helps catch levels creeping too high. At supraphysiologic doses, side effects include acne, increased facial or body hair, and rarely voice changes. These are the signal to reduce dose, not to stop treatment.
DHEA is a useful option for women who prefer a less aggressive approach or who are not candidates for direct testosterone therapy. Oral DHEA at 25 to 50 mg per day raises testosterone modestly, particularly in post-menopausal women where adrenal DHEA production has declined. A 2021 review confirmed that DHEA is a sex hormone precursor and that its age-related decline correlates with loss of libido and energy. Prasterone (Intrarosa), a vaginally administered DHEA product, holds specific FDA approval for painful sex during menopause - a narrower indication than systemic DHEA, but supported by controlled trial data.
Can Lifestyle Interventions Raise Testosterone in Women?
Resistance training raises androgen levels in women, though the effect is smaller than in men. It remains worth incorporating for its independent benefits on bone density and metabolic health.
Switching from oral to non-oral contraception is one of the highest-impact changes a woman can make when SHBG suppression is the primary driver. Oral contraceptives remain the most common iatrogenic cause of SHBG elevation and free testosterone suppression in reproductive-age women.
Sleep quality matters more than many women expect. Androgen secretion is tied to slow-wave sleep, and chronic sleep restriction leads to measurable drops in androgens. Stress reduction addresses the cortisol-DHEA axis: elevated cortisol competes with DHEA production in the adrenal glands, and prolonged high stress reduces the availability of the upstream precursor pregnenolone for sex hormone synthesis.
Frequently Asked Questions About Testosterone in Women
Can women use the same testosterone therapy as men?
Not at the same dose. Male formulations are designed for doses 10 to 20 times what a woman needs. A typical male starting dose of 50 mg testosterone gel would push a woman's total testosterone well above the physiologic female range, causing androgenic side effects including facial hair, acne, and clitoral enlargement. The formulations themselves are appropriate; the dose has to be scaled down substantially, which usually requires compounding or very careful fractionation of male products.
What labs should a woman check for testosterone?
The minimum useful panel: total testosterone by LC/MS/MS, free testosterone by equilibrium dialysis or equilibrium ultrafiltration, and SHBG. Adding DHEA-S gives information about adrenal androgen reserve. Estradiol and thyroid function (TSH, Free T3, Free T4) help rule out confounders. The DiscountedLabs Women's Hormone Panel includes DHEA-S, estradiol, progesterone, total testosterone by LC/MS/MS, free testosterone by equilibrium ultrafiltration, TSH, Free T3, and Free T4 - a comprehensive starting point without a doctor's order.
Does high SHBG cause low testosterone symptoms even when total testosterone is normal?
Yes. This is the most commonly missed scenario in women's hormone testing. A woman with total testosterone of 45 ng/dL and SHBG of 100 nmol/L can have a free testosterone level below the detection limit of most assays. Symptoms of androgen deficiency - fatigue, low libido, muscle loss - will be present despite a reassuring total T number. Treating to a total T target without addressing SHBG or switching to transdermal estrogen will not resolve the problem.
Does testosterone therapy help women with depression or fatigue?
The evidence is clearest for HSDD specifically, not for general mood or energy in women without sexual desire complaints. Some women report improved energy and emotional resilience, but this likely reflects secondary benefit - better sleep, improved libido, restored sense of well-being - rather than a direct antidepressant mechanism. A 2025 review in BJPsych Bulletin noted that while testosterone influences mood-related pathways, randomized controlled trial data for depression are not robust enough to support routine prescribing for mood alone.
How quickly does testosterone therapy work in women?
Most women notice changes in sexual desire and energy within 4 to 8 weeks of reaching target levels. Full benefit typically takes 3 to 6 months. The ISSWSH guideline recommends evaluating response at the 6-month mark before deciding whether to continue.
Conclusion
One thing most lab reports won't show you: total testosterone alone is rarely sufficient to evaluate androgen status in women. Free testosterone and SHBG together tell a far more complete story. If SHBG is driving free T toward zero, the treatment approach changes entirely - sometimes without needing any exogenous testosterone at all, just a switch from oral to transdermal estrogen.
For women pursuing this conversation with a provider, the practical starting point is a baseline panel: total T by LC/MS/MS, free T by equilibrium dialysis or ultrafiltration, SHBG, and DHEA-S together. The ISSWSH guideline recommends symptom evaluation first and lab confirmation second. Numbers don't diagnose HSDD; symptoms do.
Men on TRT often bring their partners into these conversations, having seen firsthand how hormone optimization changed their own quality of life. That shared curiosity is what drives the ExcelMale community forward. For further reading, see the ExcelMale SHBG Complete Guide and the ExcelMale HRT in Women forum.
Related ExcelMale Forum Discussions
- Testosterone and Menopause: Every Woman Should Know This - Dr. Kelly Casperson discusses what every woman should know about testosterone during menopause, covering testing, libido, treatment options, and what most doctors are still getting wrong.
- The Overlooked Benefits of Testosterone in Women - Dr. Abraham Morgentaler and colleagues discuss clinical evidence for testosterone's effects on sexual health, mood, energy, and quality of life in women.
- Testosterone in Women: Myths, Benefits & Risks of HRT After Menopause - A nuanced debate on whether menopause causes testosterone deficiency and whether supplementation is clinically warranted.
- SHBG Complete Guide: How It Controls Free Testosterone - A detailed breakdown of SHBG's role in regulating free testosterone, including how elevated SHBG affects bioavailability differently in men and women.
- What Is SHBG and How It Controls Free Testosterone - Deep dive into SHBG physiology, including binding dynamics, sex differences in SHBG concentrations, and the distinction between total and free testosterone.
- Typical HRT Dosing for Women: Can It Be Too Low? - Community discussion of HRT dosing for women, transdermal vs. injectable options, and how to recognize underdosing.
- Menopausal Hormone Therapy Use Is Beneficial Beyond Age 65 - Research review on hormone therapy for women past 65, with discussion of bioidentical options and evolving clinical recommendations.
- Updated Standards for Testing Suspected Low Testosterone in Women - Why standard immunoassay testosterone tests are inadequate for women and children, and why LC/MS/MS is the standard of care for accurate measurement.
Key References
- Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc. 2021;96(5):1238-1251. doi:10.1016/j.mayocp.2020.10.032
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603
- Wierman ME, Arlt W, Basson R, et al. Androgen Therapy in Women: A Reappraisal - An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. doi:10.1210/jc.2014-2260
- Uloko M, Rahman F, Puri LI, et al. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review. Int J Impot Res. 2022;34:635-641. doi:10.1038/s41443-022-00613-0
- Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals. 2021;15(1):46. doi:10.3390/ph15010046
- Bastawy M. Serum-level variation in testosterone (steroid hormones) and mood-related symptoms. BJPsych Bull. 2025;49(1). doi:10.1192/bjb.2024.128
- Palacios S, Minkin MJ, Genazzani AR. Challenges of prescribing testosterone for sexual dysfunction in women. Rev Assoc Med Bras. 2024;70(7):e20230839. doi:10.1590/1806-9282.20230839
- Randolph JF Jr, Zheng H, Sowers MF, et al. Change in testosterone and sex hormone-binding globulin across the stages of women's reproductive life. J Clin Endocrinol Metab. 2011;96(5):1509-1517. doi:10.1210/jc.2010-2717
About ExcelMale
ExcelMale.com is one of the largest and most active online communities for men and women exploring hormone optimization, with over 24,000 members and more than 20 years of peer-to-peer discussion on TRT, peptides, sexual health, and metabolic medicine. The forum was founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, a long-term TRT patient and patient advocate with more than 34 years of personal experience with hormone therapy.
Start Here (3K views)
